Relationship between protein biomarkers of chemotherapy response and microsatellite status, tumor mutational burden and PD‐L1 expression in cancer patients

Microsatellite instability status determined by next-generation sequencing and compared with PD-L1 and tumor mutational burden in 11,348 patients

(2018) Ari Vanderwalde et al.   Cancer Medicine

Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors

(2018) Aaron M. Goodman et al.   JAMA Oncology

Topoisomerase expression and amplification in solid tumours: Analysis of 24,262 patients

(2017) Gregory M. Heestand et al.   EUROPEAN JOURNAL OF CANCER

Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers

(2017) Aaron M. Goodman et al.   MOLECULAR CANCER THERAPEUTICS

Dosing Three‐Drug Combinations That Include Targeted Anti‐Cancer Agents: Analysis of 37,763 Patients

(2017) Mina Nikanjam et al.   ONCOLOGIST

A molecular portrait of microsatellite instability across multiple cancers

(2017) Isidro Cortes-Ciriano et al.   Nature Communications

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

(2017) Zachary R. Chalmers et al.   Genome Medicine

Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns

(2017) Mina Nikanjam et al.   OncoImmunology

Combination immunotherapy: a road map

(2017) Patrick A. Ott et al.   Journal for ImmunoTherapy of Cancer

Next generation predictive biomarkers for immune checkpoint inhibition

(2016) Yulian Khagi et al.   CANCER AND METASTASIS REVIEWS

Immunotherapy and Novel Combinations in Oncology: Current Landscape, Challenges, and Opportunities

(2016) KM Morrissey et al.   CTS-Clinical and Translational Science

Dosing targeted and cytotoxic two-drug combinations: Lessons learned from analysis of 24,326 patients reported 2010 through 2013

(2016) Mina Nikanjam et al.   INTERNATIONAL JOURNAL OF CANCER

Reliable Detection of Mismatch Repair Deficiency in Colorectal Cancers Using Mutational Load in Next-Generation Sequencing Panels

(2016) Zsofia K. Stadler et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas

(2016) Aaron Goodman et al.   Nature Reviews Clinical Oncology

Dosing de novo combinations of two targeted drugs: Towards a customized precision medicine approach to advanced cancers

(2016) Sariah Liu et al.   Oncotarget

Immuno-oncology combinations: raising the tail of the survival curve

(2016) Samuel J. Harris et al.   Cancer Biology & Medicine

Precision oncology for patients with advanced cancer: the challenges of malignant snowflakes

(2015) Razelle Kurzrock et al.   CELL CYCLE

Molecular Profiling of Infiltrating Urothelial Carcinoma of Bladder and Nonbladder Origin

(2015) Sherri Z. Millis et al.   Clinical Genitourinary Cancer

Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non–Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial

(2015) Jong-Mu Sun et al.   JOURNAL OF CLINICAL ONCOLOGY

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigms

(2015) Jennifer J. Wheler et al.   Oncotarget

Comprehensive tumor profiling identifies numerous biomarkers of drug response in cancers of unknown primary site: Analysis of 1806 cases

(2015) Zoran Gatalica et al.   Oncotarget

Unique Molecular Landscapes in Cancer: Implications for Individualized, Curated Drug Combinations

(2014) J. Wheler et al.   CANCER RESEARCH

Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence

(2014) A. R. de Biasi et al.   CLINICAL CANCER RESEARCH

ERCC1 predicts outcome in patients with gastric cancer treated with adjuvant cisplatin-based chemotherapy

(2013) Sara De Dosso et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Thymidylate Synthase Expression and Outcome of Patients Receiving Pemetrexed for Advanced Nonsquamous Non–Small-Cell Lung Cancer in a Prospective Blinded Assessment Phase II Clinical Trial

(2013) Marianne C. Nicolson et al.   Journal of Thoracic Oncology

Mutational landscape and significance across 12 major cancer types

(2013) Cyriac Kandoth et al.   NATURE

ERCC1 Isoform Expression and DNA Repair in Non–Small-Cell Lung Cancer

(2013) Luc Friboulet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Personalized Medicine in a Phase I Clinical Trials Program: The MD Anderson Cancer Center Initiative

(2012) A.-M. Tsimberidou et al.   CLINICAL CANCER RESEARCH

Topoisomerase II-alpha protein expression and histological response following doxorubicin-based induction chemotherapy predict survival of locally advanced soft tissues sarcomas

(2011) Ruiz-Soto Rodrigo et al.   EUROPEAN JOURNAL OF CANCER

Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance

(2011) Thea Eline Hetland et al.   HUMAN PATHOLOGY

Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice

(2011) W. Joost Lesterhuis et al.   JOURNAL OF CLINICAL INVESTIGATION

RRM1 expression and clinical outcome of gemcitabine-containing chemotherapy for advanced non-small-cell lung cancer: A meta-analysis

(2011) Weiyi Gong et al.   LUNG CANCER

Immune parameters affecting the efficacy of chemotherapeutic regimens

(2011) Laurence Zitvogel et al.   Nature Reviews Clinical Oncology

CD4+Foxp3+ Regulatory T-cell Impairment by Paclitaxel is Independent of Toll-like Receptor 4

(2011) Y. Zhu et al.   SCANDINAVIAN JOURNAL OF IMMUNOLOGY

Thymidylate synthase and thymidine phosphorylase as predictive markers of capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer

(2010) Su Jin Lee et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Class III  -Tubulin Expression Predicts Prostate Tumor Aggressiveness and Patient Response to Docetaxel-Based Chemotherapy

(2010) G. Ploussard et al.   CANCER RESEARCH

5-Fluorouracil Selectively Kills Tumor-Associated Myeloid-Derived Suppressor Cells Resulting in Enhanced T Cell-Dependent Antitumor Immunity

(2010) J. Vincent et al.   CANCER RESEARCH

MGMT expression levels predict disease stabilisation, progression-free and overall survival in patients with advanced melanomas treated with DTIC

(2010) Christian Busch et al.   EUROPEAN JOURNAL OF CANCER

Excision repair cross-complementation group 1 protein overexpression as a predictor of poor survival for high-grade serous ovarian adenocarcinoma

(2010) Stefanie Scheil-Bertram et al.   GYNECOLOGIC ONCOLOGY

Chemotherapy Delivered After Viral Immunogene Therapy Augments Antitumor Efficacy Via Multiple Immune-mediated Mechanisms

(2010) Zvi G Fridlender et al.   MOLECULAR THERAPY

O6-Methylguanine DNA Methyltransferase Deficiency and Response to Temozolomide-Based Therapy in Patients with Neuroendocrine Tumors

(2008) M. H. Kulke et al.   CLINICAL CANCER RESEARCH

Predictive value of thymidylate synthase expression in advanced colorectal cancer patients receiving fluoropyrimidine-based chemotherapy: Evidence from 24 studies

(2008) Li-Xin Qiu et al.   INTERNATIONAL JOURNAL OF CANCER

Predictive Biomarkers of Chemotherapy Efficacy in Colorectal Cancer: Results From the UK MRC FOCUS Trial

(2008) Michael S. Braun et al.   JOURNAL OF CLINICAL ONCOLOGY